Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells

Overview

Journal Nanomaterials (Basel)

Date 2021 Mar 6

PMID 33669332

Citations 10

Authors

Umme Ruman

Kalaivani Buskaran

Giorgia Pastorin

Mas Jaffri Masarudin

Sharida Fakurazi

Mohd Zobir Hussein

Affiliations

Soon will be listed here.

Abstract

The formation of two nanodelivery systems, Sorafenib (SF)-loaded chitosan (SF-CS) and their folate-coated (SF-CS-FA) nanoparticles (NPs), were developed to enhance SF drug delivery on human Hepatocellular Carcinoma (HepG2) and Colorectal Adenocarcinoma (HT29) cell lines. The ionic gelation method was adopted to synthesize the NPs. The characterizations were performed by DLS, FESEM, TEM, XRD, TGA, FTIR, and UV-visible spectroscopy. It was found that 83.7 ± 2.4% and 87.9 ± 1.1% of encapsulation efficiency; 18.2 ± 1.3% and 19.9 ± 1.4% of loading content; 76.3 ± 13.7 nm and 81.6 ± 12.9 nm of hydrodynamic size; 60-80 nm and 70-100 nm of TEM; and FESEM sizes of near-spherical shape were observed, respectively, for SF-CS and SF-CS-FA nanoparticles. The SF showed excellent release from the nanoparticles under pH 4.8 PBS solution, indicating a good delivery system for tumor cells. The cytotoxicity study revealed their better anticancer action towards HepG2 and HT29 cell lines compared to the free sorafenib. Moreover, both NPs systems showed negligible toxicity to normal Human Dermal Fibroblast adult cells (HDFa). This is towards an enhanced anticancer drug delivery system with sustained-release properties for better cancer management.

Citing Articles

Almond Hull Extract Valorization: From Waste to Food Recovery to Counteract and in Formation and Mature Biofilm.

DArcangelo S, Santonocito D, Messina L, Greco V, Giuffrida A, Puglia C Foods. 2024; 13(23).

PMID: 39682909 PMC: 11640323. DOI: 10.3390/foods13233834.

Stability, challenges, and prospects of chitosan for the delivery of anticancer drugs and tissue regenerative growth factors.

Rahman M, Mondal M Heliyon. 2024; 10(21):e39879.

PMID: 39583848 PMC: 11582409. DOI: 10.1016/j.heliyon.2024.e39879.

Formulation development, characterization, and evaluation of sorafenib-loaded PLGA-chitosan nanoparticles.

Mateen A, Khan A, Khan I, Ahmad L, Khan A, Salam A Front Pharmacol. 2024; 15:1465363.

PMID: 39444599 PMC: 11496126. DOI: 10.3389/fphar.2024.1465363.

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.

Avgoustakis K, Angelopoulou A Pharmaceutics. 2024; 16(2).

PMID: 38399240 PMC: 10892652. DOI: 10.3390/pharmaceutics16020179.

Cytotoxicity Enhancement of α-Mangostin with Folate-Conjugated Chitosan Nanoparticles in MCF-7 Breast Cancer Cells.

Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M Molecules. 2023; 28(22).

PMID: 38005306 PMC: 10674958. DOI: 10.3390/molecules28227585.

References

Yap T, Carden C, Kaye S . Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3):167-81. DOI: 10.1038/nrc2583. View

Lu Y, Low P . Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. J Control Release. 2003; 91(1-2):17-29. DOI: 10.1016/s0168-3659(03)00215-3. View

Rink J, Plebanek M, Tripathy S, Thaxton C . Update on current and potential nanoparticle cancer therapies. Curr Opin Oncol. 2013; 25(6):646-51. PMC: 4089948. DOI: 10.1097/CCO.0000000000000012. View

Masarudin M, Cutts S, Evison B, Phillips D, Pigram P . Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin. Nanotechnol Sci Appl. 2015; 8:67-80. PMC: 4686320. DOI: 10.2147/NSA.S91785. View

Wojcik-Pastuszka D, Krzak J, Macikowski B, Berkowski R, Osinski B, Musial W . Evaluation of the Release Kinetics of a Pharmacologically Active Substance from Model Intra-Articular Implants Replacing the Cruciate Ligaments of the Knee. Materials (Basel). 2019; 12(8). PMC: 6515312. DOI: 10.3390/ma12081202. View

Xiao Y, Liu Y, Yang S, Zhang B, Wang T, Jiang D . Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment. Colloids Surf B Biointerfaces. 2016; 141:83-92. DOI: 10.1016/j.colsurfb.2016.01.016. View

An F, Cao W, Liang X . Nanostructural systems developed with positive charge generation to drug delivery. Adv Healthc Mater. 2014; 3(8):1162-81. DOI: 10.1002/adhm.201300600. View

Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M . Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011; 6(12):815-23. DOI: 10.1038/nnano.2011.166. View

Fang C, Veiseh O, Kievit F, Bhattarai N, Wang F, Stephen Z . Functionalization of iron oxide magnetic nanoparticles with targeting ligands: their physicochemical properties and in vivo behavior. Nanomedicine (Lond). 2010; 5(9):1357-69. PMC: 3057775. DOI: 10.2217/nnm.10.55. View

10.

Kim D, Kim M, Choi C, Chung C, Ha S, Kim C . Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer. Nanoscale Res Lett. 2012; 7(1):91. PMC: 3292832. DOI: 10.1186/1556-276X-7-91. View

11.

Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade R . Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. Mater Sci Eng C Mater Biol Appl. 2019; 98:1252-1276. DOI: 10.1016/j.msec.2019.01.066. View

12.

Yosef H, Frick T, Hammoud M, Maghnouj A, Hahn S, Gerwert K . Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. Analyst. 2018; 143(24):6069-6078. DOI: 10.1039/c8an02029a. View

13.

Pawlik T, Reyes D, Cosgrove D, Kamel I, Bhagat N, Geschwind J . Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29(30):3960-7. PMC: 4829081. DOI: 10.1200/JCO.2011.37.1021. View

14.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

15.

Lu Y, Low P . Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002; 54(5):675-93. DOI: 10.1016/s0169-409x(02)00042-x. View

16.

Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad O . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2013; 66:2-25. PMC: 4219254. DOI: 10.1016/j.addr.2013.11.009. View

17.

Coriat R, Nicco C, Chereau C, Mir O, Alexandre J, Ropert S . Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012; 11(10):2284-93. DOI: 10.1158/1535-7163.MCT-12-0093. View

18.

Chang Y, Hsu W, Chang C, Lan K, Ting G, Lee T . Combined therapeutic efficacy of Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26- murine colon cancer cells. Mol Clin Oncol. 2014; 2(3):380-384. PMC: 3999117. DOI: 10.3892/mco.2014.246. View

19.

Lee M, Nah J, Kwon Y, Koh J, Ko K, Kim S . Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm Res. 2001; 18(4):427-31. DOI: 10.1023/a:1011037807261. View

20.

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View